Literature DB >> 21384333

Local expression of interleukin-27 ameliorates collagen-induced arthritis.

Sarah R Pickens1, Nathan D Chamberlain, Michael V Volin, Arthur M Mandelin, Hemant Agrawal, Masanori Matsui, Takayuki Yoshimoto, Shiva Shahrara.   

Abstract

OBJECTIVE: To determine the mechanism of action of interleukin-27 (IL-27) against rheumatoid arthritis (RA).
METHODS: Adenovirus containing IL-27 transcript was constructed and was locally delivered into the ankles of mice with collagen-induced arthritis (CIA). Progression of arthritis was determined in treated and untreated mice by measuring ankle circumference and through histologic analysis. IL-17 and its downstream targets as well as cytokines promoting Th17 cell differentiation were quantified by enzyme-linked immunosorbent assay in CIA mouse ankles locally expressing adenoviral IL-27 as well as in control-treated mouse ankles. Ankles from both treatment groups were immunostained for neutrophil and monocyte migration (macrophages in the tissue). Finally, vascularization was quantified by histology and by determining ankle hemoglobin levels.
RESULTS: Ectopic expression of IL-27 in CIA mice ameliorated inflammation, lining hypertrophy, and bone erosion as compared with control-treated CIA mice. Serum and joint levels of IL-17 were significantly reduced in the IL-27-treated group compared with the control-treated group. Two of the main cytokines that induce Th17 cell differentiation and IL-17 downstream target molecules were greatly down-regulated in CIA mouse ankles receiving forced expression of IL-27. The control mice had higher levels of vascularization and monocyte trafficking than did mice ectopically expressing IL-27.
CONCLUSION: Our results suggest that increased levels of IL-27 relieve arthritis in CIA mouse ankles. This amelioration of arthritis involves a reduction in CIA mouse serum and joint levels of IL-17 and results in decreased IL-17-mediated monocyte recruitment and angiogenesis. Hence, the use of IL-27 may be a strategy for treatment of patients with RA.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21384333      PMCID: PMC3115512          DOI: 10.1002/art.30324

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  43 in total

1.  IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis.

Authors:  Jifen Li; Bruno Gran; Guang-Xian Zhang; Abdolmohamad Rostami; Malek Kamoun
Journal:  J Neurol Sci       Date:  2005-05-15       Impact factor: 3.181

2.  Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.

Authors:  S Kotake; K Sato; K J Kim; N Takahashi; N Udagawa; I Nakamura; A Yamaguchi; T Kishimoto; T Suda; S Kashiwazaki
Journal:  J Bone Miner Res       Date:  1996-01       Impact factor: 6.741

3.  4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis.

Authors:  A E Koch; B J Nickoloff; J Holgersson; B Seed; G K Haines; J C Burrows; S J Leibovich
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

4.  Amelioration of rat adjuvant-induced arthritis by Met-RANTES.

Authors:  Shiva Shahrara; Amanda E I Proudfoot; James M Woods; Jeffrey H Ruth; M Asif Amin; Christy C Park; Christian S Haas; Richard M Pope; G Kenneth Haines; Yuan Yuan Zha; Alisa E Koch
Journal:  Arthritis Rheum       Date:  2005-06

5.  Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system.

Authors:  Jason S Stumhofer; Arian Laurence; Emma H Wilson; Elaine Huang; Cristina M Tato; Leanne M Johnson; Alejandro V Villarino; Qiulong Huang; Akihiko Yoshimura; David Sehy; Christiaan J M Saris; John J O'Shea; Lothar Hennighausen; Matthias Ernst; Christopher A Hunter
Journal:  Nat Immunol       Date:  2006-08-13       Impact factor: 25.606

6.  Interleukin-17 acts independently of TNF-alpha under arthritic conditions.

Authors:  Marije I Koenders; Erik Lubberts; Fons A J van de Loo; Birgitte Oppers-Walgreen; Liduine van den Bersselaar; Monique M Helsen; Jay K Kolls; Franco E Di Padova; Leo A B Joosten; Wim B van den Berg
Journal:  J Immunol       Date:  2006-05-15       Impact factor: 5.422

7.  IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.

Authors:  Muneo Numasaki; Mika Watanabe; Takashi Suzuki; Hidenori Takahashi; Akira Nakamura; Florencia McAllister; Takanori Hishinuma; Junichi Goto; Michael T Lotze; Jay K Kolls; Hidetada Sasaki
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

8.  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.

Authors:  Erik Lubberts; Marije I Koenders; Birgitte Oppers-Walgreen; Liduine van den Bersselaar; Christina J J Coenen-de Roo; Leo A B Joosten; Wim B van den Berg
Journal:  Arthritis Rheum       Date:  2004-02

Review 9.  Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis?

Authors:  Lisa K Stamp; Michael J James; Leslie G Cleland
Journal:  Immunol Cell Biol       Date:  2004-02       Impact factor: 5.126

Review 10.  The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models.

Authors:  Erik Lubberts; Marije I Koenders; Wim B van den Berg
Journal:  Arthritis Res Ther       Date:  2004-11-30       Impact factor: 5.156

View more
  38 in total

Review 1.  A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis.

Authors:  Brian Astry; Erin Harberts; Kamal D Moudgil
Journal:  J Interferon Cytokine Res       Date:  2011-12       Impact factor: 2.607

2.  Role of TH-17 cells in rheumatic and other autoimmune diseases.

Authors:  Michael V Volin; Shiva Shahrara
Journal:  Rheumatology (Sunnyvale)       Date:  2011-10-20

3.  Interleukin-27 suppresses osteoclastogenesis via induction of interferon-γ.

Authors:  Jin-Sil Park; Young Ok Jung; Hye-Joa Oh; Seong Jeong Park; Yu-Jung Heo; Chang-Min Kang; Seung-Ki Kwok; Ji Hyeon Ju; Kyung Su Park; Mi-La Cho; Young-Chul Sung; Sung-Hwan Park; Ho-Youn Kim
Journal:  Immunology       Date:  2012-12       Impact factor: 7.397

4.  Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27.

Authors:  Irina Kochetkova; Theresa Thornburg; Gayle Callis; Kathryn Holderness; Massimo Maddaloni; David W Pascual
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

Review 5.  IL-27: a double agent in the IL-6 family.

Authors:  G W Jones; D G Hill; A Cardus; S A Jones
Journal:  Clin Exp Immunol       Date:  2018-03-09       Impact factor: 4.330

Review 6.  Possible roles of IL-12-family cytokines in rheumatoid arthritis.

Authors:  Richard M Pope; Shiva Shahrara
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

Review 7.  Interleukin-27: balancing protective and pathological immunity.

Authors:  Christopher A Hunter; Rob Kastelein
Journal:  Immunity       Date:  2012-12-14       Impact factor: 31.745

Review 8.  IL-27-induced modulation of autoimmunity and its therapeutic potential.

Authors:  Rakeshchandra R Meka; Shivaprasad H Venkatesha; Steven Dudics; Bodhraj Acharya; Kamal D Moudgil
Journal:  Autoimmun Rev       Date:  2015-08-05       Impact factor: 9.754

Review 9.  Interleukin-27 as a potential therapeutic target for rheumatoid arthritis: has the time come?

Authors:  Fang Gong; Yu-Hong Pan; Xuan Huang; Jiang Chen; Jin-Hua Xiao; Hua-Yan Zhu
Journal:  Clin Rheumatol       Date:  2013-07-23       Impact factor: 2.980

10.  The novel role of IL-7 ligation to IL-7 receptor in myeloid cells of rheumatoid arthritis and collagen-induced arthritis.

Authors:  Zhenlong Chen; Seung-jae Kim; Nathan D Chamberlain; Sarah R Pickens; Michael V Volin; Suncica Volkov; Shiva Arami; John W Christman; Bellur S Prabhakar; William Swedler; Anjali Mehta; Nadera Sweiss; Shiva Shahrara
Journal:  J Immunol       Date:  2013-04-19       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.